Management of periorbital microcystic @entity600 with XXXX : Surgical treatment combined with intralesional @entity1732 injection.

@entity1 @entity940 @entity227 @entity600 @entity1939 @entity1732 @entity4064 @entity1736 @entity4457
OBJECTIVES: Periorbital microcystic @entity600 ( @entity600 ) can cause severe symptoms, such as @entity1736 , @entity4457 , chemosis, strabismus, @entity4064 , and @entity1939 . The purpose of this study was to evaluate the clinical outcome in periorbital microcystic @entity600 @entity1 with @entity1736 who underwent surgical treatment combined with intralesional @entity1732 injection. @entity1 AND METHODS: A retrospective study including nine @entity1 diagnosed as periorbital microcystic @entity600 with @entity1736 was conducted. All of the @entity1 underwent surgical treatment and @entity1732 injection from January 2010 to January 2014. The lesion was resected through the lower eyebrow and/or a coronal incision at the first stage, and levator resection was performed at the second stage. Any persistent lesion or its recurrence was managed by intralesional @entity1732 injection. RESULTS: @entity1736 and @entity227 were corrected in all @entity1 . Mean follow-up was 24.6months. Six @entity1 had recurrence during the follow-up, and two @entity1 who had partial eyelid closure after the second stage surgery recovered in three months. @entity4457 , @entity940 , and strabismus were not improved after treatment. All of the @entity1 had excellent aesthetic improvement and corrected @entity1736 . CONCLUSIONS: Resection through a lower eyebrow and coronal incision and levator resection performed in two stages can quickly correct the @entity227 caused by periorbital microcystic @entity600 with @entity1736 . Intralesional @entity1732 injection is a promising adjunctive therapy for residual or recurrent lesions after surgery.
